Join to View Full Profile
1515 Holcombe BlvdUnit 423Houston, TX 77030
Phone+1 713-794-5745
Fax+1 713-794-4902
Dr. Bashir is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Missouri-ColumbiaResidency, Internal Medicine, 2003 - 2006
King Edward Medical UniversityClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) Start of enrollment: 2014 Jan 01
- Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation Start of enrollment: 2019 Oct 09
Publications & Presentations
PubMed
- Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response.Oren Pasvolsky, Muhammad Bilal Abid, Denái R Milton, Mark R Tanner, Qaiser Bashir
British Journal of Haematology. 2025-03-30 - Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.Oren Pasvolsky, Curtis Marcoux, Zhongya Wang, Denái R Milton, Babar Pal
Transplantation and Cellular Therapy. 2025-03-01 - Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome.Portia Smallbone, Terri Lynn Shigle, Oren Paslovsky, Chitra Hosing, Amin Alousi
Haematologica. 2025-02-27
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
- Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature
Press Mentions
Busulfan Added to Conditioning Regimen Effective for Newly Diagnosed MyelomaMay 20th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
